Astrazeneca Ab

Christopher Thomas Halsall

Laurent Francois Andre Hennequin

Alexander Graham Dossetter

Michael Wardleworth

Iain Simpson

Bernard Christophe Barlaam

Alleyn Thomas Plowright

Janet Elizabeth Pease

Richard Andrew Ward

Kieran James Lennon

Benedicte Delouvrie

Richard Storey

Craig Steven Harris

David Alan Rudge

Peter Mark Smith

The invention concerns quinazoline derivatives of the Formula I, or pharmaceutically acceptable salts thereof: wherein each of R, R, R, Rand m are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, and, for example, EGFR tyrosine kinase.

Quinazoline derivatives as tyrosine kinase inhibitors

The invention concerns quinazoline derivatives of Formula (I), wherein each of R, R, R, Rand a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases. 

Quinazoline derivatives as antiproliferative agents

There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

Compounds

A quinazoline derivative of the formula I: wherein: R, R, R, R, R, R, RR, R, a, m and p are as defined in the description. Also claimed are pharmaceutical compositions containing the quinazoline derivative, the use of the quinazoline derivatives as medicaments and processes for the preparation of the quinazoline derivative. The quinazoline derivatives of formula I, are useful in the treatment of hyperproliferative disorders such as a cancer.

Quinazoline compounds for the treatment of hyperproliferative disorders

The invention concerns quinazoline derivatives of the Formula (I); wherein each of R, R, W, X, X, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase. 

The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds 

3-aminoalkyl-2-aryl-indole derivatives and their use as GnRH antagonists

The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds.

Growing community of inventors

Macclesfield, United Kingdom

Christopher Thomas Halsall